LEADER 03509nam 2200697 a 450 001 9910779864903321 005 20200520144314.0 010 $a0-7425-6042-2 010 $a1-4422-2572-6 035 $a(CKB)2550000001100308 035 $a(EBL)1315701 035 $a(OCoLC)852898460 035 $a(SSID)ssj0000918115 035 $a(PQKBManifestationID)12401870 035 $a(PQKBTitleCode)TC0000918115 035 $a(PQKBWorkID)10893437 035 $a(PQKB)11785932 035 $a(MiAaPQ)EBC1315701 035 $a(Au-PeEL)EBL1315701 035 $a(CaPaEBR)ebr10734573 035 $a(CaONFJC)MIL504734 035 $a(EXLCZ)992550000001100308 100 $a20130610d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 14$aThe global president$b[electronic resource] $einternational media and the US government /$fStephen J. Farnsworth, S. Robert Lichter, and Roland Schatz 210 $aLanham, Md. $cRowman & Littlefield Publishers, Inc.$d2013 215 $a1 online resource (217 p.) 300 $aDescription based upon print version of record. 311 $a0-7425-6043-0 311 $a1-299-73483-9 320 $aIncludes bibliographical references and index. 327 $aContents; List of Tables; Acknowledgments; Ch01. Global Communication and the US Government; Ch02. The World Is Watching, Don't Look Back: News about US Politicians, People, and Policies; Ch03. The Obama Presidency: International Media Perspectives; Ch04. The George W. Bush Presidency: International Media Perspectives; Ch05. US Foreign Policy and International News: Comparing Obama and Bush; Ch06. International News Perspectives on the 2008 US Presidential Election; Ch07. Globalization, International News, and the US Government; Appendix. THE MEDIA TENOR CONTENTANALYSIS DATA; References 327 $aIndex 330 $aWhen the US government speaks, the world listens, regardless of whether people like what they hear. News reporters and citizens around the world pay considerable attention to the statements of US presidents and the actions of the US government. In The Global President: International Communication and the US Government, scholars Stephen J. Farnsworth, S. Robert Lichter and Roland Schatz provide an expansive international examination of news coverage of US political communication, and the roles the US government and the Presidency play in an increasingly communicative and interconnec 606 $aCommunication in politics$zUnited States 606 $aCommunication, International 606 $aPresidents$zUnited States$xPublic opinion 606 $aPresidents$xPress coverage$zUnited States 606 $aMass media$xPolitical aspects$zUnited States$xPublic opinion 607 $aUnited States$xPolitics and government$y21st century 607 $aUnited States$xForeign public opinion 615 0$aCommunication in politics 615 0$aCommunication, International. 615 0$aPresidents$xPublic opinion. 615 0$aPresidents$xPress coverage 615 0$aMass media$xPolitical aspects$xPublic opinion. 676 $a327.73001/4 700 $aFarnsworth$b Stephen J.$f1961-$01542475 701 $aLichter$b S. Robert$01542476 701 $aSchatz$b Roland$01542477 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910779864903321 996 $aThe global president$93795256 997 $aUNINA LEADER 04840nam 22009253u 450 001 9910146397303321 005 20231129014806.0 010 $a1-280-30974-1 010 $a9786610309740 010 $a1-84692-556-8 035 $a(CKB)1000000000463450 035 $a(EBL)362703 035 $a(OCoLC)476194143 035 $a(SSID)ssj0000258330 035 $a(PQKBManifestationID)12112418 035 $a(PQKBTitleCode)TC0000258330 035 $a(PQKBWorkID)10257141 035 $a(PQKB)10109792 035 $a(EXLCZ)991000000000463450 100 $a20130418d2005|||| u|| | 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aTherapeutic Strategies in Lymphoid Malignancies$b[electronic resource] $eAn Immunotherapeutic Approach 210 $aOxford $cAtlas Medical Publishing Ltd$d2005 215 $a1 online resource (238 p.) 225 1 $aTherapeutic Strategies 300 $aDescription based upon print version of record. 311 $a1-904392-52-0 327 $aContents; Contributors; 1. The history of immunotherapy for lymphoid malignancies; 2. Immunological markers of lymphoid malignancy; 3. Diagnostic and prognostic markers of lymphoid malignancies; the latest genetic, cytogenetic and haematological parameters; 4. CD20: B-cell antigen and therapeutic target; 5. Rituximab and chemotherapy for non-Hodgkin's lymphomas: improved response and survival; 6. Rituximab and chemotherapy in elderly patients with lymphomas; 7. Maintenance therapy with rituximab; 8. Interferon-alpha in lymphoid malignancies 327 $a9. Radioimmunotherapy safety: radiation protection, administration guidelines, isotope comparison, and quality of life issues10. Radioimmunotherapy with Yttrium-90-labelled ibritumomab tiuxetan (ZevalinTM) for B-cell Hodgkin's lymphoma; 11. Radioimmunotherapy combinations with other therapies for non-Hodgkin's lymphoma; 12. 131I-Tositumomab therapy for the treatment ofl ow-grade non-Hodgkin's lymphoma; 13. CD52 as a target for immunotherapy; 14. Relapsed and refractory CLL: a clinical challenge 327 $a15. Optimising the use of alemtuzumab in CLL: new therapeutic end points, disease stratification and therapy earlier in the disease course16. Alemtuzumab in combination with other therapies in B-cell lymphoproliferative disorders; 17. The role of alemtuzumab in allogeneic stem cell transplantation; 18. Alemtuzumab in T-cell malignancies; 19. Epratuzumab: A new humanised monoclonal antibody to CD22; 20. Education and management of patients undergoing immunotherapy and radioimmunotherapy; 21. Antibody therapy for chronic lymphocytic leukemia; Index 330 $aTargeted therapies are the focus of much research in oncology. Encouraging results from the development of new monoclonal antibodies are revolutionizing clinical therapies and this is particularly the case for haematologic malignancies. The advent of immunotherapy heralds a new era particularly for patients who are refractory to more traditional therapies. Impressive results are evident using monoclonal antibodies (mAb) that a) bind with high specificity to cell-surface antigens, resulting in targeted killing of the malignant cells or b) are conjugated to radioisotopes, toxins, enzymes or drug 410 0$aTherapeutic Strategies 606 $aCancer 606 $aLymphatics 606 $aLymphoma 606 $aLymphoma 606 $aImmunotherapy 606 $aLymphoproliferative Disorders 606 $aNeoplasms by Histologic Type 606 $aImmunomodulation 606 $aLymphatic Diseases 606 $aBiological Therapy 606 $aImmunoproliferative Disorders 606 $aNeoplasms 606 $aImmune System Diseases 606 $aDisease 606 $aTherapeutics 606 $aHemic and Lymphatic Diseases 606 $aDiagnostic Techniques and Procedures 615 4$aCancer. 615 4$aLymphatics. 615 4$aLymphoma. 615 2$aLymphoma. 615 2$aImmunotherapy. 615 2$aLymphoproliferative Disorders. 615 2$aNeoplasms by Histologic Type. 615 2$aImmunomodulation. 615 2$aLymphatic Diseases. 615 2$aBiological Therapy. 615 2$aImmunoproliferative Disorders. 615 2$aNeoplasms. 615 2$aImmune System Diseases. 615 2$aDisease. 615 2$aTherapeutics. 615 2$aHemic and Lymphatic Diseases. 615 2$aDiagnostic Techniques and Procedures. 676 $a616.994420637 700 $aHillmen$b P$01001216 701 $aWitzig$b TE$01001217 801 0$bAU-PeEL 801 1$bAU-PeEL 801 2$bAU-PeEL 906 $aBOOK 912 $a9910146397303321 996 $aTherapeutic Strategies in Lymphoid Malignancies$92298040 997 $aUNINA